Pollen AllergyNCT03727399
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
An observational study of Pollen Allergy, run by Mabylon AG at 1 site in Switzerland.
Trial summary
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pollen Allergy
- What is being tested?
- blood withdrawal
- How many people
- 300 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Oct 2018to 31 Dec 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The project population will include adult (> 18 years) patients with a history of grass and birch pollen allergy verified by positive skin prick test and allergen-specific IgE in blood. The study population may also include patients with ongoing or completed AIT.
Who may be able to join
- History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
- Male or female patients older than 18 years
- Written informed consent for providing blood and also to allow experimental manipulation
Who cannot join
- Age < 18 years
- Any corticosteroids within the last three days
- Oral corticosteroid therapy within the last ten days
- Parenteral depot corticosteroids within the last three months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site
Immunologie Zentrum Zürich
Zurich, Canton of Zurich, 8006
About this study
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
- Conditions
- Pollen Allergy
- Being tested
- blood withdrawal
- Medical subject headings
- Rhinitis, Allergic, Seasonal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood withdrawalOther
Blood withdrawal
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibody profiling
Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.
Measured: October 2018 - September 2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2018
- Study start1 Oct 2018
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pollen AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mabylon AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03727399
- Sponsor's protocol ID
- 2018-01110
- Other IDs
- 2018
- Status last verified
- Oct 2026
- First submitted
- 31 Oct 2018
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No